NasdaqCM - Delayed Quote USD

Assertio Holdings, Inc. (ASRT)

0.8656 -0.0439 (-4.83%)
At close: April 24 at 4:00 PM EDT
0.8700 +0.00 (+0.51%)
After hours: April 24 at 7:16 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Heather L. Mason Interim CEO & Director 92.5k -- 1960
Mr. Bill Iskos Senior Vice President of Operations -- -- --
Ms. Molly Dir Senior Vice President of HR & Administration ? -- -- --
Dr. Howard J. Franklin M.B.A., M.D. Senior Vice President of Medical -- -- --

Assertio Holdings, Inc.

100 South Saunders Road
Suite 300
Lake Forest, IL 60045
United States
224 419 7106 https://www.assertiotx.com
Sector: 
Healthcare
Full Time Employees: 
53

Description

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Corporate Governance

Assertio Holdings, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 1; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Assertio Holdings, Inc. Earnings Call

Related Tickers

SCYX SCYNEXIS, Inc.
1.5000
-3.23%
 
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
 
AQST Aquestive Therapeutics, Inc.
3.9000
-8.88%
 
IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%
 
AMRX Amneal Pharmaceuticals, Inc.
6.05
+12.04%
 
DERM Journey Medical Corporation
3.4000
-3.95%
 
DVAX Dynavax Technologies Corporation
11.42
-2.89%
 
COLL Collegium Pharmaceutical, Inc.
35.48
-1.28%
 
OPTN OptiNose, Inc.
0.9253
-4.38%
 
AVDL Avadel Pharmaceuticals plc
17.66
-2.38%